[1]孟召伟,贾强.Midkine在甲状腺癌标志物中的价值[J].国际放射医学核医学杂志,2018,(4):369-372,376.[doi:10.3760/cma.j.issn.1673-4114.2018.04.015]
　Meng Zhaowei,Jia Qiang.The value of Midkine as a thyroid cancer marker[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(4):369-372,376.[doi:10.3760/cma.j.issn.1673-4114.2018.04.015]
点击复制

Midkine在甲状腺癌标志物中的价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
期数:
2018年第4期
页码:
369-372,376
栏目:
综述
出版日期:
2018-07-25

文章信息/Info

Title:
The value of Midkine as a thyroid cancer marker
作者:
孟召伟;  贾强
300052, 天津医科大学总医院核医学科
Author(s):
Meng Zhaowei;  Jia Qiang
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin 300052, China
关键词:
甲状腺肿瘤; Midkine; 标志物
Keywords:
Thyroid neoplasms; Midkine; Marker
DOI:
10.3760/cma.j.issn.1673-4114.2018.04.015
摘要:
Midkine（MK）有多重生物学功能，对肿瘤的诊治具有重要作用。MK在不同的肿瘤中高度表达，促进癌细胞增殖、迁移和新生血管形成。近年来的研究发现，MK和甲状腺癌关系密切。免疫组化研究表明，MK在甲状腺癌细胞和组织中的表达明显高于正常甲状腺。甲状腺结节穿刺洗脱液的MK水平对甲状腺结节的良恶性判断有很好的诊断价值。MK是可分泌到血液中的细胞因子，其作为血清学标志物可以判断甲状腺结节良恶性，对分化型甲状腺癌131I治疗的预后（是否存在转移病灶）有明确的判断价值。在甲状腺球蛋白抗体阳性的情况下，MK可作为预测分化型甲状腺癌转移的有效血清学标志物。MK的最大局限性是肿瘤特异性差，很多情况下，需要和其他特异性强的肿瘤标志物联合测定。今后的研究重点是MK在甲状腺癌发生、发展和治疗耐药机制方面的探讨。笔者主要综述MK在甲状腺癌标志物中的价值。
Abstract:
Midkine (MK) has multiple biological functions, and plays an important role in the diagnosis and treatment of tumor. Midkine is generally overexpressed in diverse malignant tumors, and enhances proliferation, migration and angiogenic activity of tumor cells. Recent studies have found that MK is closely related with thyroid cancer. Immunohistochemical studies showed that MK expression in thyroid cancer cells and tissues was significantly higher than that of normal thyroid. MK level of the needle aspiration eluant had a good diagnostic value for the differentiationbetween benign and malignant thyroid nodules. MK is cytokinesecreted in the blood; it could be used as a serological marker for the differentiation between benign and malignant thyroid nodules. MK could also beapplied for the prognosis of differentiated thyroid carcinoma treated by 131I (whether with or without metastases). In addition, in the case of thyroglobulin antibody positivity, MK could be surrogated as a viable serological marker for predicting thyroid cancer metastasis. The major limitation of MK is lowoncological specificity. In many cases, it is necessary to measure MK with other specific tumor markers. Future researches should focus on the mechanism of MK in the occurrence, development and therapeutic resistance of thyroid cancer. This review discusses the value of MK as a thyroid cancer marker.

参考文献/References:

[1] Muramatsu T, Kadomatsu K. Midkine:an emerging target of drug development for treatment of multiple diseases[J]. Br J Pharmacol, 2014, 171(4):811-813. DOI:10.1111/bph.12571.
[2] Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects[J]. Br J Pharmacol, 2014, 171(4):814-826. DOI:10.1111/bph.12353.
[3] Tian W, Shen J, Chen W. Suppression of midkine gene promotes the antitumoral effect of cisplatin on human gastric cancer cell line AGS in vitro and in vivo via the modulation of Notch signaling pathway[J]. Oncol Rep, 2017, 38(2):745-754. DOI:10.3892/or.2017. 5743.
[4] Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma[J]. Clin Cancer Res, 2013, 19(14):3944-3954. DOI:10.1158/1078-0432.CCR-12-3363.
[5] Sun B, Hu C, Yang Z, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells[J]. Oncotarget, 2017, 8(20):32523-32535. DOI:10.18632/oncotarget.15808.
[6] Vongsuvanh R, van der Poorten D, Iseli T, et al. Midkine Increases Diagnostic Yield in AFP Negative and NASH-Related Hepatocellular Carcinoma[J/OL]. PLoS One, 2016, 11(5):e0155800[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC48-78793. DOI:10.1371/journal.pone.0155800.
[7] Yamashita T, Shimada H, Tanaka S, et al. Serum midkine as a biomarker for malignancy, prognosis, and chemosensitivity in head and neck squamous cell carcinoma[J]. Cancer Med, 2016, 5(3):415-425. DOI:10.1002/cam4.600.
[8] Xia X, Lu JJ, Zhang SS, et al. Midkine is a serum and urinary biomarker for the detection and prognosis of non-small cell lung cancer[J]. Oncotarget, 2016, 7(52):87462-87472. DOI:10.18632/oncotarget.13865.
[9] Ak G, Tada Y, Shimada H, et al. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin[J]. BMC Cancer, 2017, 17(1):212. DOI:10.1186/s12885-017-3209-5.
[10] Jones DR. Measuring midkine:the utility of midkine as a biomarker in cancer and other diseases[J]. Br J Pharmacol, 2014, 171(12):2925-2939. DOI:10.1111/bph.12601.
[11] Dianat N, Le VB, Gobbo E, et al. Midkine lacking its last 40 amino acids acts on endothelial and neuroblastoma tumor cells and inhibits tumor development[J]. Mol Cancer Ther, 2015, 14(1):213-224. DOI:10.1158/1535-7163.MCT-14-0226.
[12] Rawnaq T, Dietrich L, Wolters-Eisfeld G, et al. The multifunctional growth factor midkine promotes proliferation and migration in pancreatic cancer[J]. Mol Cancer Res, 2014, 12(5):670-680. DOI:10.1158/1541-7786. MCR-13-0467.
[13] Kato M, Maeta H, Kato S, et al. Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma[J]. Mod Pathol, 2000, 13(10):1060-1065. DOI:10.1038/modpathol.3880195.
[14] Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer[J]. Endocrine, 2014, 46(2):285-291. DOI:10.1007/s12020-013-0068-y.
[15] Choi YW, Kim YH, Lee J, et al. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma[J]. Hum Pathol, 2015, 46(10):1557-1565. DOI:10.1016/j.humpath.2015.06.018.
[16] Zhang Y, Meng Z, Zhang M, et al. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis[J]. Life Sci, 2014, 118(1):39-45. DOI:10.1016/j.lfs.2014.09.025.
[17] Jee YH, Celi FS, Sampson M, et al. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules[J]. Clin Endocrinol (Oxf), 2015, 83(6):977-984. DOI:10.1111/cen.12676.
[18] Kuzu F, Arpaci D, Unal M, et al. Midkine:A Novel Biomarker to Predict Malignancy in Patients with Nodular Thyroid Disease[J]. Int J Endocrinol, 2016, 2016:6035024[2018-01-07]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944023.DOI:10.1155/2016/6035024.
[19] Meng Z, Tan J, Zhang G, et al. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer[J]. Life Sci, 2015,130:18-24. DOI:10.1016/j.lfs.2015.02.028.
[20] Jia Q, Meng Z, Xu K, et al. Serum midkine as a surrogate biomarker for metastatic prediction in differentiated thyroid cancer patients with positive thyroglobulin antibody[J/OL]. Sci Rep, 2017, 7:43516[2018-01-07]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378906. DOI:10.1038/srep43516.
[21] Jing X, Cui X, Liang H, et al. Diagnostic accuracy of ELISA for detecting serum Midkine in cancer patients[J/OL]. PLoS One, 2017, 12(7):e018051[2018-01-08]. https://www.ncbi.nlm.nih.gov/pubmed/28686647. DOI:10.1371/journal.pone.0180511.
[22] Masui M, Okui T, Shimo T, et al. Novel Midkine Inhibitor iMDK Inhibits Tumor Growth and Angiogenesis in Oral Squamous Cell Carcinoma[J]. Anticancer Res, 2016, 36(6):2775-2781.
[23] Sun B, Hu C, Yang Z, et al. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells[J]. Oncotarget, 2017, 8(20):32523-32535. DOI:10.18632/oncotarget.15808.
[24] Ishida N, Fukazawa T, Maeda Y, et al. A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor[J]. Exp Cell Res, 2015, 335(2):197-206. DOI:10.1016/j.yexcr.2015.03.019.
[25] Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer[J]. N Engl J Med, 2013, 368(7):623-632. DOI:10.1056/NEJMoa1209288.

相似文献/References:

[1]李盼丽,宋少莉.碘难治性分化型甲状腺癌靶向药物治疗进展[J].国际放射医学核医学杂志,2016,40(3):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
　Li Panli,Song Shaoli.Radioactive iodine refractory differentiated thyroid cancer targeted therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):202.[doi:10.3760/cma.j.issn.1673-4114.2016.03.009]
[2]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[3]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[4]惠金子,赵德善.Tg、TgAb及TSH在分化型甲状腺癌术前的预测分析[J].国际放射医学核医学杂志,2015,39(2):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
　Hui Jinzi,Zhao Deshan.The prediction of risk of differentiated thyroid carcinoma with preoperative serum thyroid stimulating hormone, thyrogiobulin and antithyroglobulin antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):110.[doi:10.3760/cma.j.issn.1673-4114.2015.02.002]
[5]刘斌,潘明志.BRAF基因突变对甲状腺乳头状癌诊治价值的研究进展[J].国际放射医学核医学杂志,2015,39(2):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
　Liu Bin,Pan Mingzhi.Advances in value of BRAF gene mutation on the diagnosis and treatment of papillary thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):154.[doi:10.3760/cma.j.issn.1673-4114.2015.02.011]
[6]胡斌,王锦锋,毛秋粉.18F-FDG PET/CT显像在Tg阳性131I全身显像阴性的分化型甲状腺癌患者中的应用价值[J].国际放射医学核医学杂志,2015,39(3):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
　Hu Bin,Wang Jinfeng,Mao Qiufen.The application value of 18F-FDG PET/CT in patients with differentiated thyroid cancer of high thyroglobulin level and negative 131I whole body scan[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):242.[doi:10.3760/cma.j.issn.1673-4114.2015.03.012]
[7]刘鹏杰,唐铭,邓智勇,等.131I治疗儿童分化型甲状腺癌期间出现低钙血症伴癫痫发作一例[J].国际放射医学核医学杂志,2015,39(4):352.[doi:10.3760/cma.j.issn.1673-4114.2015.04.017]
[8]寇莹,刘建中,郝新忠,等.甲状腺癌131I治疗后全身扫描盆腔浓聚131I的临床分析[J].国际放射医学核医学杂志,2014,38(1):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
　Kou Ying,Liu Jianzhong,Hao Xinzhong,et al.Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):15.[doi:10.3760/cma.j.issn 1673-4114.2014.01.004]
[9]李敬彦,蒋宁一.分化型甲状腺癌术后131I清甲治疗方法的相关问题[J].国际放射医学核医学杂志,2014,38(1):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
　Li Jingyan,Jiang Ningyi.Issues related to radioactive iodine ablation in patients with differentiated thyroid carcinoma under-going thyroid surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):42.[doi:10.3760/cma.j.issn 1673-4114.2014.01.009]
[10]成钊汀,谭建.分化型甲状腺癌术后患者131I治疗的辐射剂量与防护[J].国际放射医学核医学杂志,2014,38(2):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]
　Cheng Zhaoting,Tan Jian.Radiation dose and protection of differentiated thyroid carcinoma postoperative patients with 131I treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(4):110.[doi:10.3760/cma.j.issn.1673-4114.2014.02.010]

备注/Memo

备注/Memo:
收稿日期:2018-01-08。
基金项目:国家自然科学基金（81571709）；天津市自然科学基金重点项目（16JCZDJC34300）
通讯作者:孟召伟,Email:jamesmencius@163.com
更新日期/Last Update: 2018-07-25